Company intelligence / Profile preview

Wuhan Renfu Innovative Drug R&D Center

Wuhan, Hubei Province, China

Ownership: Private
Development stage: Phase 2

Overview

Wuhan Renfu Innovative Drug Research and Development Center is an active pharmaceutical research subsidiary focused on the development of innovative drugs, with at least one small molecule candidate approved for clinical trials targeting advanced solid tumors as of September 2024. The center operates under the parent company Humanwell Healthcare Group/Renfu Pharmaceutical.

Therapeutic areas: Oncology
Modalities: Small molecules (confirmed by clinical trial approval for a tablet drug)
Industry: Biotech

Drug pipeline

2 assets

HZ-J001

Phase 2

Indications: vitiligo, atopic dermatitis, alopecia areata

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Wuhan Renfu Innovative Drug R&D Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Renfu Innovative Drug R&D Center.

Explore the full profile